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Solubility tests and the peripheral blood film method for 
screening for sickle-cell disease: A cost benefit analysis
Andrew Livex Okwi, Michael Ocaido, Wilson Byarugaba, Christopher Magala Ndugwa, Arthur Parkes
Sickle-cell disease (SCD) is one of the haemoglobinopathies 
responsible for high morbidity and mortality among neonates 
in developing countries, including Uganda.1 It is therefore 
necessary to establish the most cost-effective screening and 
intervention programmes to reduce morbidity and mortality 
among children with SCD.2 However, most governments in 
developing countries, including Uganda, cannot fund all the 
necessary medical programmes because of scarce resources. 
Cost benefit analyses are therefore performed to determine 
which programmes or options offer the greatest benefits at the 
lowest cost.3,4
While some developing countries such as Jamaica and Ghana 
have made progress in introducing comprehensive sickle-cell 
screening programmes,5,6 the peripheral blood film method 
for screening for SCD at district health centres has been 
recommended in Kenya.7 In Malawi, the most cost-effective 
haemoglobinopathy testing methods have been recommended 
to be used at district hospitals.8
Since no cost benefit analysis (CBA) studies have been done 
on sickle-cell screening methods in Uganda, we studied the 
cost benefit of screening for SCD among infants at district 
health centres using the sickling and solubility tests and the 
peripheral blood film method.
Methods and materials
Pilot screening services were established using sickling and 
solubility tests and the peripheral blood film method at each 
selected health centre in each district where medical laboratory 
technicians had been trained. The trained technicians screened 
for SCD using these methods and then delivered blood samples 
to the Faculty of Medicine at Mulago Hospital, to be analysed 
using cellulose acetate membrane haemoglobin electrophoresis 
(gold standard).9 Each batch of assays included a negative 
control (haemoglobin AA) and positive control (haemoglobin 
SS).
CBA performed under several assumptions and different 
scenarios determined the benefits and/or profitability of each 
method. Cumulative costs in USh and benefits were compared 
over a 5-year period.
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Objective. To determine the cost benefit of screening for sickle-
cell disease among infants at district health centres in Uganda 
using sickling, solubility tests and the peripheral blood film 
method.
Methods. Pilot screening services were established at district 
health centres. Cost benefit analysis (CBA) was performed in 
four scenarios: A1 – where there are no sickle-cell screening 
services at district health centres and all children are referred 
either to Mulago national referral hospital or A2 – a regional 
hospital for haemoglobin (Hb) electrophoresis; B1 – when 
there are screening services at district health centres, only 
positive samples are taken either to Mulago Hospital or B2 
– the regional hospital for confirmation using haemoglobin 
electrophoresis. Calculations were done in Uganda shillings 
(USh).
Results. Initial operational costs were high for all scenarios but 
variably reduced in the subsequent years. Scenarios A1 and 
A2 were very sensitive compared with B1 and B2. Scenario 
A1 had the highest screening costs in the subsequent years, 
costing over 62 000 USh per test in both eastern and western 
Uganda. Scenario B2 was sensitive and cheaper when using 
the sickling test, but was expensive and insensitive when 
using the solubility test and more insensitive though cheaper 
when using the peripheral blood film method.
Conclusions and recommendation. Screening children in Mulago 
Hospital using haemoglobin electrophoresis (A1) was very 
expensive although it was sensitive. Screening the children at 
four health centres using the sickling method and confirming 
positive samples at a regional hospital (B2) was both cheap 
and sensitive and is therefore recommended.
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Analysis was based on the following assumptions:
•   Each of the sickle-cell screening methods established at the 
district health centre would be the recommended screening 
method for SCD.
•   The automated capillary haemoglobin electrophoresis 
system would be used in Mulago and regional hospitals as a 
‘gold standard’.
•   All children testing negative at district health centres are 
considered free of the disease except those who later develop 
symptoms.
•   Only children who test positive at the district health centres 
will have confirmatory testing, and those confirmed positive 
would benefit from interventions and survive.
•   Screening costs only, and not treatment costs, will be 
considered.
•   Persons performing these tests would also be doing routine 
work and would be paid a monthly salary.
•   Glassware not falling under consumables would be replaced 
in the second year.
•   The costs of running sickle-cell tests took into account the 
regional prevalence of SCD among newborn children.
•   The haemoglobin electrophoresis machine would depreciate 
at USh 11 571 750 per year, while each microscope and 
weighing balance would depreciate at USh 300 000 and USh  
50 280 per year, respectively.
•   95% of children with the sickle cell trait (AS) would live a 
normal life, and 85% with sickle cell anemia (SS) would live to 
adulthood if diagnosed and appropriately treated.10
The following scenarios were used:
•   A1: there are no sickle-cell screening services at district 
health centres and regional hospitals, and all children are 
referred to Mulago Hospital for haemoglobin electrophoresis
•   A2: there are no screening services at district health centres 
and all children are referred to the regional hospital for 
haemoglobin electrophoresis
•   B1: there are sickle-cell screening services at district health 
centres and only positive samples are brought to Mulago 
Hospital
•   B2: there are screening services at district health centres and 
only positive samples are brought to the regional hospital for 
confirmation.
Results
Technicians took an average of 38 minutes to prepare the 
sickling test solution and perform the test, and an average 
of 70 minutes to prepare working solutions and perform 
the solubility test. Preparing peripheral blood film method 
solutions and performing the test took an average of 44 
minutes. Technicians took 6 minutes on average to bleed each 
child.
A total of 286 children were screened in eastern Uganda 
(March - May 2007) and 370 in western Uganda (June - August 
2007). In eastern Uganda, haemoglobin electrophoresis detected 
50 AS and 5 SS cases , while the sickling test demonstrated 
the presence of 26 AS, 5 SS, the solubility test 13 AS, 4 SS 
and the peripheral blood film method 7 AS and 2 SS. In the 
west, haemoglobin electrophoresis detected 11 AS and no SS, 
while the sickling test demonstrated the presence of 5 AS, the 
solubility test 3 AS and the peripheral smear 2 AS. Reliability 
was performed separately using haemoglobin electrophoresis 
as a gold standard, and a sample size of 200 blood samples 
was used. The sickling test had the highest sensitivity and 
specificity of 65% and 95% respectively compared with 
solubility, which had 45% and 90%, and peripheral blood film 
35% and 96.7%, respectively.11
In scenario A1, the cost of USh 75 665 253 would be incurred 
in the first 3 months in eastern Uganda and USh 61 822 853 
would be incurred if scenario A2 intervention activities were 
adopted, thereby saving USh 13 842 400. In western Uganda, 
USh 82 005 135 would be incurred in scenario A1 and USh  
63 727 135 would in scenario A2, thereby saving USh  
18 278 000 (Table I).
It would cost USh 65 991 528 using the sickling test in 
eastern Uganda in the first 3 months in scenario B1 and USh  
65 433 528 in B2, thereby saving USh 558 000. In western 
Uganda USh 66 633 583 would be needed in the first 3 months 
in B1 and USh 65 993 583 in B2, thereby saving USh 640 000 
(Table II).
Using the solubility test, USh 63 530 316 would be spent in 
eastern Uganda in the first 3 months under scenario B1 and 
USh 62 972 316 under B2 – a saving of USh 558 000. In western 
Uganda, USh 64 128 213 would be incurred in scenario B1 and 
USh 63 488 213 under B2, therefore saving USh 640 000 (Table 
III).
Using the peripheral blood film method, it would cost USh 
65 769 148 in the east in the first 3 months using scenario B1, 
and USh 65 211 148 in B2, thereby saving USh 558 000. In the 
west, USh 66 469 264 would be incurred in scenario B1 in the 
first 3 months, and USh 65 829 264 in B2, thereby saving  
640 000 (Table IV).
These screening programmes would all save the same 
amount of money in the first 3 months in both eastern and 
western Uganda.
The costs of the screening services were projected for a 
period of 5 years, and it was assumed that more children with 
SCD would be detected and more money would be saved 
because the only costs incurred would be service maintenance 
costs. These were calculated annually on the incremental 
basis of 3% of the previous year’s maintenance costs, since 
there would be an expected 3% annual increase in the general 
population.12 Other costs included depreciation of laboratory 
equipment calculated at each closing fiscal year by dividing the 
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total cost of the equipment by its useful life years, taken as 5 
years for medical equipment.13
When the sickling test is used together with the haemoglobin 
electrophoresis method, USh 9 565 912 would be incurred 
in eastern Uganda under scenario B1 and USh 7 147 912 in 
scenario B2 in year 1, thereby saving USh 2 418 000. In western 
Uganda, USh 10 920 130 would be incurred in scenario B1 and 
USh 8 840 130 in scenario B2, thereby saving USh 2 080 000. 
Table III. Costs (USh) incurred in first 3 months on children in eastern and western Uganda in scenarios B1 and B2  using 
solubility test
                  Eastern Uganda               Western Uganda
Variable      Scenario B1 Scenario B2 Scenario B1 Scenario B2
Automated Hb electrophoresis   57 858 750 57 858 750 57 858 750 57 858 750
Consumables for Hb electrophoresis    153 698  153 698  170 775  170 775
Training while establishing solubility    2 261 000  2 261 000  2 280 000  2 280 000
screening services
Equipment, materials and consumables    1 480 820  1 480 820  1 592 070  1 592 070
for solubility method
Transport of mothers to health centre   858 000  858 000  1 100 000  1 100 000
Loss of productivity costs    48 048  48 048  62 160  62 160
Health staff delivering positive samples   870 000  0  1 184 000  0
to Mulago hospital
Health staff delivering positive samples   0  312 000  0  544 000
to regional hospital
   Total      63 530 316 62 972 316 64 128 213 63 488 213
   Cost per test     222 134  220 183  173 321  171 590
Table II. Costs (USh) incurred in the first 3 months on children in scenarios B1 and B2 in eastern and western Uganda when 
using sickling test and automated Hb electrophoresis as screening methods
                  Eastern Uganda             Western Uganda
Variable      Scenario B1 Scenario B2 Scenario B1 Scenario B2
Automated Hb electrophoresis   57 858 750 57 858 750 57 858 750 57 858 750
Consumables for Hb electrophoresis     204 930  204 930  51 233  51 233
Training during establishing sickling   2 261 000  2 261 000  2 280 000  2 280 000
screening services
Equipment, materials and consumables    3 890 800  3 890 800  4 097 440  4 097 440
for sickling method
Transport of mothers to health centre   858 000  858 000  1 100 000  1 100 000
Loss of productivity     48 048  48 048  62 160  62 160
One health staff delivering positive    870 000  0  1 184,000  0
samples to Mulago Hospital
Health staff  delivering positive samples   0  312 000  0  544 000
to regional hospital
   Total      65 991 528 65 433 528 66 633 583 65 993 583
   Cost per test     230 740  228 689  180 091  178 361
Table I. Costs (USh) incurred in the first 3 months on children in scenarios A1  and A2 in eastern and western Uganda when 
using automated Hb electrophoresis as screening method
                  Eastern Uganda             Western Uganda
Variable      Scenario A1 Scenario A2 Scenario A1  Scenario A2
Automated Hb electrophoresis   57 858 750 57 858 750 57 858 750 57 858 750
Consumables for Hb electrophoresis   1 628 055  1 628 055  2 106 225  2 106 225
Transport of mothers to Mulago,    16 130 400 0  21 978 000 0
maintenance plus accommodation
Transport of mothers to regional hospital  0  2 288 000  0  3 700 000
Loss of productivity costs    48 048  48 048  62 160  62 160
   Total      75 665 253 61 822 853 82 005 135 63 727 135
   Cost per test     262 902  216 164  221 635  172 235
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Using the solubility method, it would cost USh 11 766 602 in year 
1 under scenario B1 and USh 9 348 602 in B2 in eastern Uganda, 
therefore saving USh 2 418 000. In western Uganda, a cost of USh 
13 376 820 and USh 11 296 820 would be incurred in scenario 
B1 and B2 respectively, thereby saving USh 2 080 000. When the 
peripheral blood film method is used, USh 8 876 392 would be 
incurred in year 1 under scenario B1 and USh 6 458 392 in B2 
in eastern Uganda, saving USh 2 418 000. In western Uganda, 
a cost of USh 10 262 854 would be incurred under scenario B1 
and USh 8 182 854 under scenario B2, thereby saving USh  
2 080 000. More money would be saved in the subsequent 
years. 
Discussion
Cost benefit analyses are useful to identify the cheapest 
interventions with highest benefits.3 This was done on the 
solubility and sickling tests and the peripheral blood film 
method to determine the most cost-effective method for 
screening for SCD among neonates in the districts of Uganda.
The cost-effectiveness of screening for SCD was sensitive 
to various variables. As expected, it was sensitive to the 
prevalence, cost and reliability of the screening programme. 
While over USh 75 million would be incurred in scenario 
A1 in eastern Uganda in the first 3 months and more than 
USh 63 million in scenario A2, 50 children with AS and 5 
with SS would be detected in eastern Uganda by A1 and A2,  
respectively.
While more than USh 82 million would be incurred on A1 
in western Uganda and 63 million in B2, only 11 children 
with AS would be identified by both scenarios in the first 
3 months. These differences were probably due to the 
high prevalence of SCD in eastern Uganda and the high 
reliability of the haemoglobin electrophoresis method. These 
findings agree with studies which found that identifying 
sick persons in a population with low prevalence or risk of 
the disease was associated with very high costs.2,14 Therefore 
screening the population in western Uganda, which has a 
very low prevalence of AS and SS, using the haemoglobin 
electrophoresis method would not be cost effective because of 
the high cost of identifying these children. In eastern Uganda 
the same programme would cost-effectively identify many of 
these children.3
Whereas both the sickling test and peripheral blood film 
method were more expensive than the solubility test in the 
first 3 months because of the high costs of equipment, they 
subsequently became cheaper. Although scenarios B2 and 
B1 were not as sensitive as scenarios A1 and A2, scenario B2 
demonstrated the same number of cases with SS as scenarios 
A1 and A2 at low cost when using the sickling test, implying 
that the sickling method could cheaply and reliably be used 
for early detection of children with haemoglobin SS. Although 
the peripheral blood method for sickle-cell screening at district 
health centres has been recommended,7 we found it insensitive 
but cheap.
Scenarios A1 and A2 would continue saving more money 
throughout the subsequent years, while in scenarios B1 and 
B2 the same amount of money would be saved in both eastern 
and western Uganda. While the reasons for this are difficult 
to explain, some costs were estimated and were therefore not 
accurate, and could have influenced the findings.
Conclusions and recommendations
Screening all children in Mulago Hospital using haemoglobin 
electrophoresis (scenario A1) was sensitive but not cost 
beneficial. We recommend screening all the children at sub-
district health centres by means of the sickling method and 
confirming only positive samples at a regional hospital (B2), as 
it was the most cost-effective intervention.
We thank Innovations at Makerere University Committee (I@Mak.
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Table IV. Costs (USh) incurred using peripheral blood film method in first 3 months on children in eastern and western 
Uganda in scenarios B1 and B2
                  Eastern Uganda             Western Uganda
Variable      Scenario B1 Scenario B2 Scenario B1 Scenario B2
Automated Hb electrophoresis   57 858 750 57 858 750 57 858 750 57 858 750
Consumables for Hb electrophoresis consumables  79 695  79 695  39 848  39 848
Training during establishing peripheral blood   2 261 000  2 261 000  2 280 000  2 280 000
film screening  services
Equipment, materials and consumables for   3 793 655  3 793 655  3 944 506  3 944 506
peripheral blood film method
Transport of mothers to health centre   858 000  858 000  1 100 000  1 100 000
Loss of productivity costs    48 048  48 048  62 160  62 160
Health staff delivering positive samples to Mulago hospital 870 000  -  1 184 000  -
Health staff delivering positive samples to regional hospital -  312 000  -  544 000
   Total      65 769 148 65 211 148 66 469 264 65 829 264
   Cost per test     229 962  228 011  179 647  177 917
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